Company intelligence / Profile preview

Hygga

Shenzhen, Guangdong, Chinahyggasolutions.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Hygieia Biotech has commercialized high-purity nicotinamide mononucleotide (NMN) using proprietary enzymatic processes. Their products are third-party tested and used as raw materials in supplements and cosmetics. They participate in industry standard-setting and collaborate with research institutions to explore new indications.

Therapeutic areas: OtherMetabolic Disorders
Modalities: Small moleculeEnzymeProtein
Industry: Non-Drug Biotech

Partnerships

Collaborations with domestic and international research institutions; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on Hygga.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hygga.

Explore the full profile